Oncology Institute (TOI) EBITDA (2020 - 2026)

Oncology Institute has reported EBITDA for 7 years, with the latest figure at -$5.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 36.94% year-over-year to -$5.6 million; the trailing twelve-month figure through Mar 2026 stood at -$28.8 million (up 40.64% YoY), and the FY2025 full-year result was -$32.1 million, up 43.58% from the prior year.
• EBITDA for Q1 2026 stood at -$5.6 million, up from -$6.0 million in the prior quarter.
• The five-year high for EBITDA was -$5.6 million in Q1 2026, with the low at -$32.3 million in Q1 2023.
• Historically, EBITDA has averaged -$14.7 million across 5 years, with a median of -$14.3 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA slumped 1802.97% — and 2025, when it soared 48.43%.
• Oncology Institute's EBITDA stood at -$24.6 million in 2022, then soared by 41.18% to -$14.5 million in 2023, then gained by 24.06% to -$11.0 million in 2024, then soared by 45.51% to -$6.0 million in 2025, then gained by 6.34% to -$5.6 million in 2026.
• The last three EBITDA figures came in at -$5.6 million (Q1 2026), -$6.0 million (Q4 2025), and -$7.0 million (Q3 2025), per Business Quant data.